Login / Signup

BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes.

Yu-Li ChenHan-Wei LinChung-Liang ChienYen-Ling LaiWei-Zen SunChi-An ChenWen-Fang Cheng
Published in: Journal for immunotherapy of cancer (2019)
The Trial Registration Number was NCT00854399.
Keyphrases
  • cancer therapy
  • drug delivery
  • high glucose
  • clinical trial
  • diabetic rats
  • study protocol
  • peripheral blood
  • phase iii
  • phase ii
  • randomized controlled trial
  • drug induced
  • oxidative stress
  • stress induced